REGULATORY

Pharma, Healthcare Circle See “Off-Year” Drug Re-Pricing Unrealistic amid Coronavirus Crisis

March 25, 2020
While the first “off-year” drug price revision looms in April next year, many in the pharmaceutical industry and healthcare community now see it difficult to implement the plan as scheduled as the government scrambles to rein in the spread of…

To read the full story

Related Article

REGULATORY

By Philip Carrigan

If you were able to make more money at a company you found less desirable than your current one, would it be worth it? Conversely, would you move to a better company and a better role and accept less pay?…

By Takashi Ohama

Over two years after the rollout of the cost-effectiveness assessment (CEA) scheme in April 2019, discussions on its system reform are set to go into full swing at a key reimbursement policy council known as Chuikyo. Both payer and healthcare…

The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…

By Yoshinori Sagehashi

Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…